Dynavax Technologies Corporation Stock Nasdaq
Equities
US2681581029
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Financials (USD)
Sales 2024 * | 285M | Sales 2025 * | 349M | Capitalization | 1.51B |
---|---|---|---|---|---|
Net income 2024 * | 18M | Net income 2025 * | 47M | EV / Sales 2024 * | 3.36 x |
Net cash position 2024 * | 556M | Net cash position 2025 * | 683M | EV / Sales 2025 * | 2.38 x |
P/E ratio 2024 * |
72.2
x | P/E ratio 2025 * |
32.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.66% |
Latest transcript on Dynavax Technologies Corporation
Managers | Title | Age | Since |
---|---|---|---|
Ryan Spencer
CEO | Chief Executive Officer | 46 | 04-12-31 |
David Novack
PSD | President | 62 | 13-03-24 |
Patricia Novy
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Francis Cano
BRD | Director/Board Member | 79 | 09-11-02 |
Peggy Phillips
BRD | Director/Board Member | 70 | 06-07-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 10-07-21 |
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |